Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
87
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease

Antoni Sicras Mainar1 Scientific Direction, Health Economics and Outcomes Research (HEOR) Department, Real Life Data, Madrid, Spain
,
Alicia Huerta2 Market Access Department, GlaxoSmithKline SA, Madrid, SpainCorrespondence[email protected]
,
Ruth Navarro Artieda3 Medical Documentation Department, Hospital Germans Trias I Pujol, Badalona, Spain
,
Eduard Monsó4 Pulmonology Service, Hospital Parc Taulí, Barcelona, Spain;5 CIBERES – Ciber De Enfermedades Respiratorias, Madrid, Spain
,
Sarah H Landis6 Real World Evidence and Epidemiology Department, GlaxoSmithKline, Uxbridge, UK
&
Afisi S Ismaila7 Value Evidence and Outcomes Department, GlaxoSmithKline, Collegeville, PA, USA;8 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
Pages 2121-2129 | Published online: 12 Sep 2019

References

  • Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2019 Report. Global Initiative for Chronic Obstructive Lung Disease. Available from: http://www.goldcopd.org. Accessed 806, 2019.
  • Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-817765528
  • Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
  • Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow-up study. Thorax. 2004;59(5):387–395. doi:10.1136/thx.2003.00873015115864
  • Soler-Cataluna JJ, Martínez-García MM, Román-Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi:10.1136/thx.2005.04052716055622
  • Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
  • Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD. A summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946.15219010
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
  • Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
  • Bogart M, Glassberg MB, Reisch T, Stanford RH. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respir Med. 2018;145:138–144. doi:10.1016/j.rmed.2018.10.01330509702
  • Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.3558716
  • Ministerio de Sanidad Servicios Sociales e Igualdad. Information about the products included in the pharmaceutical provision of the SNS (dispensable through pharmacies). 2018 Available from: http://www.msssi.gob.es/en/profesionales/nomenclator.do. Accessed 806, 2019.
  • Thompson SG, Barber JA. How should cost data in pragmatic randomised clinical trials be analysed? BMJ. 2000;1197–1200. doi:10.1136/bmj.320.7243.119710784550
  • Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9):e105296. doi:10.1371/journal.pone.010529625180802
  • Barrecheguren M, Monteagudo M, Ferrer J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47–53. doi:10.1016/j.rmed.2015.12.00426758585
  • Calle Rubio M, Alcázar Navarrete B, Soriano JB, et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulmon Dis. 2017;12:417–426. doi:10.2147/COPD.S12448228182155
  • Hurst JR, Dileen M, Morris K, Hills S, Emir B, Jones R. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:781–792. doi:10.2147/COPD.S15365529551894
  • Landis SH, Wirst K, Le HV, Bonar K, Punekar YS. Can assessment of disease burden prior to changes in initial COPD maintenance treatment provide insight into remaining unmet needs? A retrospective database study in UK primary care. COPD. 2017;14(1):80–85. doi:10.1080/15412555.2016.124015927819513
  • Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther. 2008;30:Spec No:1003–1016. doi:10.1016/j.clinthera.2008.05.020
  • de Miguel Diez J, Carrasco Garrido P, García Carballo M, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4):701–712.19281084
  • Sicras A, Huerta A, Navarro R, Ibáñez J. Use of resources and associated costs of chronic obstructive pulmonary disease exacerbations: a population based retrospective study. Semergen. 2014;40:189–197. doi:10.1016/j.semerg.2013.10.00224485969

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.